TenCure
Cancer Drug Development
Company Overview
Snapshot
Founded in September 2012 by Tamar Tennenbaum, PhD, MD, TenCure operated with 1–10 employees. The company ceased operations in March 2020.
Business overview
TenCure was a biopharmaceutical company focused on developing personalized oncology therapeutics for epithelial solid tumors, including skin, colon, and pancreatic cancers. The company aimed to establish a diverse pipeline of oncology therapies, specifically targeting niche markets with unmet medical needs. TenCure's core technology involved identifying a new mechanism within the insulin signaling pathway that influences cancer formation and progression, developing inhibitory agents to deactivate these targets. These drug candidates were designed to inhibit cancer cell proliferation, eradicate tumors, and suppress malignant tumor progression, providing novel therapies for solid cancer indications resistant to current treatments. The company operated within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What was TenCure's primary focus?
- TenCure was a biopharmaceutical company focused on developing personalized oncology therapeutics for epithelial solid tumors, including skin, colon, and pancreatic cancers.
- When was TenCure founded?
- TenCure was founded in September 2012.
- Who was a key founder of TenCure?
- Tamar Tennenbaum, PhD, MD was a founder of TenCure.
- What was TenCure's operational status?
- TenCure ceased to operate in March 2020.
- What was TenCure's core technological approach?
- TenCure identified a new mechanism within the insulin signaling pathway affecting cancer formation and progression, developing inhibitory agents to deactivate these targets for novel cancer therapies.